4.2 Article

Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Hematology

Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities

Arwa Z. Al-Riyami et al.

Summary: This paper discusses key gaps in knowledge regarding the clinical application of convalescent plasma for treating COVID-19, focusing on areas such as study design, patient eligibility, CCP dosing and administration frequency, assessment of response to treatment and long-term outcomes, adverse events, as well as CCP application in resource-limited countries and specific populations such as children. Further research is needed to address these gaps and provide better evidence on the effectiveness and safety of CCP use.

VOX SANGUINIS (2021)

Review Health Care Sciences & Services

Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis

Meng Wang et al.

Summary: Hydroxychloroquine, LPV/r, and Arbidol have limited benefits in COVID-19 treatment, while integrative Chinese-Western medicine can improve patient symptoms. Remdesivir and convalescent plasma may be potential treatments for severe COVID-19 patients, pending large-scale clinical trials to validate conclusions.

BMJ SUPPORTIVE & PALLIATIVE CARE (2021)

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells

Jian Zheng et al.

Summary: Studies have shown that SARS-CoV-2 infection of immature macrophages and dendritic cells leads to failed replication but induces the production of various antiviral and proinflammatory cytokines, ultimately causing cell death mediated by interferon. Activation and death of macrophages are not enhanced even when exposed to low levels of convalescent plasma.

JOURNAL OF INFECTIOUS DISEASES (2021)

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Infectious Diseases

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal et al.

Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.

EUROSURVEILLANCE (2021)

Review Immunology

Convalescent plasma in Covid-19: Possible mechanisms of action

Manuel Rojas et al.

AUTOIMMUNITY REVIEWS (2020)

Editorial Material Hematology

COVID-19 convalescent plasma: phase 2

C. Michael Knudson et al.

TRANSFUSION (2020)

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Sean T. H. Liu et al.

NATURE MEDICINE (2020)

Article Medical Laboratory Technology

Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays

Anna E. Merrill et al.

JOURNAL OF APPLIED LABORATORY MEDICINE (2020)